Conference Coverage on DMD and LGMD: Latest Developments

CME: 0.5

Program Overview

Until very recently, the only treatment available for DMD was corticosteroids. While clinicians are likely to be well aware of corticosteroids and their utility in the management of DMD, they are less likely to be aware of newer therapeutic options. Given the multisystem involvement of DMD, multidisciplinary management is important, yet this is still not a standard practice. Physicians are likely unaware of mutation-specific targeted therapies presently under development for LGMD. While there are no therapies presently approved for LGMD, several gene therapy trials in clinical stages are underway. These videos share the latest updates in these areas as presented at a recent neuromuscular meeting.

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Review new clinical information on the management of patients with DMD and LGMD presented at major congresses
  • Discuss the implication of this information on current clinical practices for clinicians

Post a comment to this article